Overview
Sanyou Bio has built the "Sanyou Super Trillion Innovative Antibody Drug Discovery Technology Platform", featuring technology integration to completely solve the problem of screening innovative antibody candidate molecules.
The platform integrates nine super-trillion antibody libraries, with a super-large storage capacity of ten trillion; thousands of leading molecules are guaranteed, and eukaryotic proteins are escorted; molecular forms such as single domains, monoclonal antibodies, polyclonal antibodies, peptides, and small proteins are fully covered and are suitable for targeting biopharmaceutical development in tumors, autoimmunity, neurology, metabolism, ophthalmology, and other fields.
Service Process
Service Content
Service Advantages
Application
Solution
Case study
Case 1 CD100 Fully Human Antibody
Fully human antibody A screened by STML 从STML. The affinity and blocking activity of the preferred A is significantly superior to those of the Benchmarker. The antibody A is significantly superior to Benchmarker in inhibiting MDSC cell proliferation. In Vivo efficacy validation showed that the antitumor effect of antibody A combining with PD-L1 monoclonal antibody (P18) was significantly better than that of the control antibody combining with PD-L1 monoclonal antibody.
Fig.1 Binding affinity determination by FACS
Fig.2 Blocking activity determination by FACS
Fig.3 MDSC proliferation inhibition
Fig.4 Tumor growth inhibition
Case 2 Bispecific Neutralizing Antibody Against SARS-COV-2
The results showed that SYZJ001 bispecific antibody was superior to any monoclonal antibody or monoclonal antibody combination in blocking the binding of the RBD protein on AEC2-HEK293 cells. The results showed the bispecific antibody had the best virus neutralization activity, which was superior to the monoclonal antibodies constituting the bispecific antibody and the combination of monoclonal antibodies. It shall be the first-in-class bispecific antibody against COVID-19 that applied for IND.
Fig.5 Blocking activity of RBD to ACE2-HEK293
Fig.6 Virus neutralization activity
Fig.7 Virus neutralizing activity in vivo
Case 3 Development of anti-ROR1 ADC drug
Antibodies obtained from the STML have good affinity. Besides，binding affinity in vitro is 2 times higher that that of the control antibody. The affinity of the candidate antibodies to ROR1-HEK293 cells by FACS indicates that the candidate antibodies are comparable to the control antibody.
Fig. 8 Affinity ranking of antigen
Fig. 9 Affinity ranking of tumor cells
Fig.10 ADC killing assay test on tumor cells
Case 4 Development of anti- Claudin18.2 CAR-T drug
The affinity of C2 antibodies is superior to those of the control antibodies. The binding activity of C2 antibody at cellular level is superior to that of the control antibodies. Validation of pharmacodynamics showed that the CDC killing effect of candidate antibody C2 on human CLDN18.2-HEK293T cells is comparable to that of control antibody. Validation of pharmacodynamics showed that the candidate antibody C2 completely inhibited tumor growth at 0.4 MPK and showed an extremely excellent antitumor effect.
Fig.11 Binding affinity determination by FACS
Fig.12 ADCC assay on human CLDN18.2-HEK293T cell
Fig.13 CDC assay on human CLDN18.2-HEK293T cell
Fig.14 Tumor growth inhibition
Achievements
Inquriy
Inquiry